School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Australia.
School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Australia.
Clin Nutr. 2016 Apr;35(2):331-336. doi: 10.1016/j.clnu.2015.04.004. Epub 2015 Apr 13.
The high incidence of cardiovascular disease (CVD) in chronic kidney disease (CKD) is related partially to chronic inflammation. n-3 Fatty acids have been shown to have anti-inflammatory effects and to reduce the risk of CVD. Specialized Proresolving Lipid Mediators (SPMs) derived from the n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) actively promote the resolution of inflammation. This study evaluates the effects of n-3 fatty acid supplementation on plasma SPMs in patients with CKD.
In a double-blind, placebo-controlled intervention of factorial design, 85 patients were randomized to either n-3 fatty acids (4 g), Coenzyme Q10 (CoQ) (200 mg), both supplements, or control (4 g olive oil), daily for 8 weeks. The SPMs 18-HEPE, 17-HDHA, RvD1, 17R-RvD1, and RvD2, were measured in plasma by liquid chromatography-tandem mass spectrometry before and after intervention.
Seventy four patients completed the 8 weeks intervention. n-3 Fatty acids but not CoQ significantly increased (P < 0.0001) plasma levels of 18-HEPE and 17-HDHA, the upstream precursors to the E- and D-series resolvins, respectively. RvD1 was significantly increased (P = 0.036) after n-3 fatty acids, but no change was seen in other SPMs. In regression analysis the increase in 18-HEPE and 17-HDHA after n-3 fatty acids was significantly predicted by the change in platelet EPA and DHA, respectively.
SPMs are increased after 8 weeks n-3 fatty acid supplementation in patients with CKD. This may have important implications for limiting ongoing low grade inflammation in CKD.
慢性肾脏病（CKD）患者心血管疾病（CVD）发病率高，部分与慢性炎症有关。ω-3 脂肪酸具有抗炎作用，可降低 CVD 风险。源于 ω-3 脂肪酸二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的特异性促解决脂质介质（SPM）可积极促进炎症消退。本研究评估了ω-3 脂肪酸补充剂对 CKD 患者血浆 SPM 的影响。
在一项双盲、安慰剂对照的二因子设计干预研究中，85 名患者被随机分为 ω-3 脂肪酸（4 g）、辅酶 Q10（CoQ）（200 mg）、两者联合补充剂或安慰剂（4 g 橄榄油）组，每日 1 次，持续 8 周。采用液相色谱-串联质谱法检测干预前后患者血浆中 SPMs 18-HEPE、17-HDHA、RvD1、17R-RvD1 和 RvD2 的水平。
74 名患者完成了 8 周的干预。与 CoQ 组相比，仅 ω-3 脂肪酸组（P < 0.0001）显著增加了 18-HEPE 和 17-HDHA 水平，分别为 E 系列和 D 系列消退素的上游前体。n-3 脂肪酸组 RvD1 水平显著升高（P = 0.036），但其他 SPM 无变化。在回归分析中，n-3 脂肪酸组 18-HEPE 和 17-HDHA 的增加与血小板 EPA 和 DHA 的变化显著相关。
8 周ω-3 脂肪酸补充后，CKD 患者 SPM 增加。这可能对限制 CKD 持续低度炎症具有重要意义。
